Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Gastric Cancer”

182 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 182 results

Testing effectiveness (Phase 2)Study completedNCT01522768
What this trial is testing

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Who this might be right for
Esophageal CancerGastric Cancer
Memorial Sloan Kettering Cancer Center 42
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06492317
What this trial is testing

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
The First Affiliated Hospital of Zhengzhou University 20
Not applicableStudy completedNCT04920747
What this trial is testing

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

Who this might be right for
HER2-positive Gastric CancerMetastatic CancerDocetaxel+1 more
Centre Hospitalier Universitaire de Besancon 65
Testing effectiveness (Phase 2)Ended earlyNCT05555251
What this trial is testing

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Metastatic Breast Cancer+2 more
BioInvent International AB 18
Testing effectiveness (Phase 2)Study completedNCT01503983
What this trial is testing

Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive

Who this might be right for
Stage IV Gastric Cancer With Metastasis
Fundación para el Progreso de la Oncología en Cantabria 45
Early research (Phase 1)Study completedNCT03650348
What this trial is testing

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more
Pieris Pharmaceuticals, Inc. 41
Early research (Phase 1)UnknownNCT05315830
What this trial is testing

HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Who this might be right for
Adenocarcinoma - GEJAdenocarcinoma of the Stomach
The First Affiliated Hospital of Bengbu Medical University 10
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Not applicableUnknownNCT01847794
What this trial is testing

HER2 Positive CTC in Advanced Gastric Cancer

Who this might be right for
HER2 Positive Advanced Gastric Cancer
Peking University 50
Testing effectiveness (Phase 2)Ended earlyNCT02726399
What this trial is testing

Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Memorial Sloan Kettering Cancer Center 7
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Large-scale testing (Phase 3)Not Yet RecruitingNCT07332533
What this trial is testing

KN026-based Combination Therapy in HER2-positive Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
Shanghai JMT-Bio Inc. 490
Testing effectiveness (Phase 2)Ended earlyNCT05091528
What this trial is testing

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more
Silverback Therapeutics 2
Large-scale testing (Phase 3)Looking for participantsNCT06532006
What this trial is testing

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Who this might be right for
Gastroesophageal-junction CancerMonoclonal AntibodyGastric Cancer+1 more
Shanghai Henlius Biotech 550
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Large-scale testing (Phase 3)Study completedNCT01774786
What this trial is testing

Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 780
Not applicableStudy completedNCT01295086
What this trial is testing

Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer

Who this might be right for
Adenocarcinoma
Odense University Hospital 27
Testing effectiveness (Phase 2)UnknownNCT02901301
What this trial is testing

Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer

Who this might be right for
Gastric Cancer
Yonsei University 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT05190445
What this trial is testing

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Who this might be right for
HER2-positive Gastric Cancer
Pieris Pharmaceuticals, Inc. 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04430738
What this trial is testing

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Who this might be right for
Colorectal CarcinomaGastric AdenocarcinomaGEJ Adenocarcinoma+3 more
Seagen, a wholly owned subsidiary of Pfizer 40
Load More Results